Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: A combined analysis of external evidence and clinical expertise

M. Speakman, J. Batista, R. Berges, E. Chartier-Kastler, G. Conti, F. Desgrandchamps, K. Dreikorn, F. Lowe, M. O'Leary, M. Perez, J. Trachtenberg, A. Tubaro, B. Meesen, L. Smets, H. Stoevelaar

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The RAND appropriateness method was used to explore the relevance of risk factors for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). A total of, 12 international experts assessed the appropriateness of various treatments for 243 risk profiles. Highest appropriateness rates were found for α1-adrenoceptor antagonists (68% of profiles) and combination therapy (46%). A large prostate volume was the dominant argument in favour of 5α-reductase inhibitors and combination therapy, but was irrelevant for the choice of surgery. Considerable postvoid residual, severe symptoms and poor maximum flow rate were the most important factors in favour of surgery.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume8
Issue number4
DOIs
Publication statusPublished - Dec 1 2005

    Fingerprint

Keywords

  • Benign prostatic hyperplasia
  • Evidence-based medicine
  • Lower urinary tract symptoms
  • RAND appropriateness method
  • Risk factors

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this